Status:
RECRUITING
A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC
Lead Sponsor:
National Cancer Centre, Singapore
Conditions:
Advanced EGFR Exon 20 Insertion Mutated Non-Small Cell Lung Cancer
Eligibility:
All Genders
21-99 years
Brief Summary
There are limited in depth studies on the epidemiology and clinical management of EGFR exon 20 insertion mutated NSCLC in Asia. In addition, there is preliminary data suggesting the exact location of ...
Detailed Description
This study will be a multi-center observational study and will enroll patients with advanced EGFR exon 20 insertion mutated NSCLC. The study will include patients recruited from countries across Asia...
Eligibility Criteria
Inclusion Criteria:
- Histologically confirmed advanced NSCLC
- Positive testing result from any locally approved test (including but not limited to RT-PCR, Cobas and NGS) for EGFR exon 20 insertion mutation
- Diagnosis date from 1 Jan 2013 to 31 Dec 2024 (to allow for minimum 12 months of follow-up clinical and treatment outcome data)
- Male or female adults, age as defined by local regulations
Exclusion Criteria:
1. Patients without an EGFR exon 20 insertion mutation
Key Trial Info
Start Date :
March 15 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT06418412
Start Date
March 15 2024
End Date
December 31 2026
Last Update
June 12 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Centre, Singapore
Singapore, Singapore, 168583
2
Seoul National University Hospital
Seoul, South Korea
3
National Taiwan University Hospital
Taipei, Taiwan